# OnCo record kras-g12c-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/kras-g12c-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "kras-g12c-nsclc" ;
  schema:name "KRAS G12C-mutant non-small-cell lung cancer"@en ;
  schema:alternateName "KRAS G12C lung cancer"@en, "KRAS-mutant NSCLC"@en, "KRAS p.G12C non-small-cell lung cancer"@en ;
  schema:description "KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."@en ;
  schema:url <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KRAS> ;
  schema:citation <https://en.wikipedia.org/wiki/KRAS>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/garsorasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/merck/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/tps/> ;
  onco:trials <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct07190248/> ;
  onco:people <https://onco.cc/people/kevan-shokat/>, <https://onco.cc/people/ferdinandos-skoulidis/>, <https://onco.cc/people/pasi-janne/>, <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/ramaswamy-govindan/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/>, <https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/> ;
  onco:pipeline <https://onco.cc/drugs/divarasib/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/garsorasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/trials/nct07190248/>, <https://onco.cc/ideas/idea-bio1-pmhc-bispecifics-public-drivers/>, <https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/terms/tps/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/drugs/daraxonrasib/> .